Stereotactic Body Radiotherapy for Oligometastatic and Oligoprogressive Genitourinary Malignancies: A Work in Progress.

For their review in this issue of European Urology Oncology, Huynh and colleagues [1] coordinated an impressive collaboration of international experts to enter the admittedly crowded space of reviews on stereotactic body radiotherapy (SBRT) for oligometastatic prostate cancer. As clinicians who treat prostate cancer usually treat other genitourinary malignancies, this article also provides a useful summary of published prospective trials examining the role of SBRT for oligometastatic kidney and bladder cancer.